PMNProMIS Neurosciences, Inc.

Sign up free

Market reactionShares rose 14% on Nov 6.

IntactLast material event Aug 13, 2026 · Updated Oct 25, 2026

ProMIS expects unblinded 12-month PRECISE-AD data for PMN310 in early Alzheimer's disease in the first quarter of 2027, after a blinded interim showed no ARIA-E in 136 patients; cash of $53.4 million is expected to last through 2027

ProMIS Neurosciences is a clinical-stage company developing PMN310, an antibody designed to bind only toxic amyloid-beta oligomers, for early Alzheimer's disease; it is not approved.

ProMIS' case rests on PMN310, an antibody designed to bind only toxic amyloid-beta oligomers in Alzheimer's disease, aiming to avoid the brain swelling and bleeding (ARIA) seen with approved antibodies. In a blinded six-month interim of 136 patients in the PRECISE-AD Phase 1b, no ARIA-E occurred, but pooled biomarker changes cannot show efficacy. Unblinded topline results, including cognitive measures, are expected in the first quarter of 2027, and cash of $53.4 million should fund operations through 2027.

Thesis checklist

0 risks need attention

Select a row for evidence
Unblinded PRECISE-AD data show a drug effectAwaiting evidenceNext: Unblinded topline results (first quarter of 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

No ARIA-E through 12 monthsSupportedNext: Full 12-month safety data (first quarter of 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts through 2027SupportedNext: Q3 cash balance.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

PRECISE-AD 12-month topline results

Tests: Unblinded PRECISE-AD data show a drug effect

First quarter of 2027

Do unblinded results show PMN310 lowering Alzheimer's biomarkers versus placebo while ARIA stays rare?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical
+23.9%Aug 13, 2026

ProMIS expects unblinded 12-month PRECISE-AD data for PMN310 in early Alzheimer's disease in the first quarter of 2027, after a blinded interim showed no ARIA-E in 136 patients; cash of $53.4 million is expected to last through 2027

IntactRegulatory
+154.6%Jul 22, 2025

PMN310 Fast Track Designation granted

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Mild cognitive impairment due to Alzheimer's disease· mild Alzheimer's disease
PMN310 · 1 upcoming · 2 completed
Phase 1b Data: ToplinePRECISE-AD
Q1 2027
Parkinson's disease· dementia with Lewy bodies · multiple system atrophy
PMN442 · 1 upcoming
IND-enabling studies start
TBD

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the ProMIS Neurosciences (PMN) investment thesis intact?
Yes. Readouts currently rates the ProMIS Neurosciences Thesis Intact. ProMIS expects unblinded 12-month PRECISE-AD data for PMN310 in early Alzheimer's disease in the first quarter of 2027, after a blinded interim showed no ARIA-E in 136 patients; cash of $53.4 million is expected to last through 2027.
What is the next catalyst for ProMIS Neurosciences (PMN)?
The next dated event is Phase 1b topline results (PRECISE-AD) for PMN310, expected Q1 2027, as stated by the company.
How long will ProMIS Neurosciences' cash last?
ProMIS Neurosciences has said its cash will fund operations through 2027 (guidance as of August 13, 2026).

Other companies we cover in these diseases

Parkinson's disease
Alterity Therapeutics (ATHE)

Disease areas: Neurology and pain
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

17 peers tracked

For informational purposes only—not investment advice. Always conduct your own research before making investment decisions.

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.